85,652 Shares in Glaukos Corporation $GKOS Bought by M&G PLC

M&G PLC purchased a new stake in shares of Glaukos Corporation (NYSE:GKOS) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 85,652 shares of the medical instruments supplier’s stock, valued at approximately $14,047,000. M&G PLC owned about 0.14% of Glaukos at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in GKOS. BlackRock Inc. acquired a new stake in shares of Glaukos in the second quarter valued at about $1,333,318,000. Jupiter Topco LLC acquired a new position in shares of Glaukos in the second quarter worth approximately $679,614,000. Primecap Management Co. CA acquired a new position in shares of Glaukos in the second quarter worth approximately $424,969,000. Janus Henderson Group PLC boosted its holdings in Glaukos by 77.2% in the first quarter. Janus Henderson Group PLC now owns 5,348,395 shares of the medical instruments supplier’s stock valued at $575,844,000 after acquiring an additional 2,329,608 shares during the last quarter. Finally, William Blair Investment Management LLC bought a new stake in Glaukos in the second quarter valued at approximately $92,476,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Insider Activity

In other news, Director Gilbert Kliman sold 2,500 shares of the firm’s stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $253.00, for a total transaction of $632,500.00. Following the completion of the sale, the director directly owned 37,406 shares of the company’s stock, valued at $9,463,718. This trade represents a 6.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 5.90% of the stock is currently owned by corporate insiders.

Glaukos Price Performance

Glaukos stock opened at $236.81 on Wednesday. Glaukos Corporation has a 52 week low of $87.32 and a 52 week high of $255.18. The company’s 50 day moving average price is $180.57 and its two-hundred day moving average price is $145.22. The stock has a market cap of $14.02 billion, a P/E ratio of -80.55 and a beta of 0.68. The company has a quick ratio of 4.09, a current ratio of 4.57 and a debt-to-equity ratio of 0.09.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.57. Glaukos had a negative return on equity of 0.97% and a negative net margin of 24.60%. The company had revenue of $211.03 million during the quarter, compared to the consensus estimate of $168.04 million. During the same period last year, the business posted ($0.16) earnings per share. Glaukos’s revenue was up 58.0% on a year-over-year basis. On average, equities analysts predict that Glaukos Corporation will post 0.50 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on GKOS. Citigroup increased their target price on shares of Glaukos from $225.00 to $247.00 and gave the company a “buy” rating in a research report on Thursday, October 29th. JPMorgan Chase & Co. upped their price objective on shares of Glaukos from $200.00 to $240.00 and gave the company an “overweight” rating in a research note on Thursday, October 29th. Wells Fargo & Company upped their price objective on shares of Glaukos from $178.00 to $226.00 and gave the company an “overweight” rating in a research note on Thursday, October 29th. Jefferies Financial Group increased their price objective on shares of Glaukos from $190.00 to $210.00 and gave the stock a “buy” rating in a research report on Tuesday, September 22nd. Finally, Stifel Nicolaus lifted their target price on shares of Glaukos from $190.00 to $225.00 and gave the stock a “buy” rating in a research note on Thursday, October 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $216.71.

Glaukos Profile

Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.